Dear Members,

"Wishing you all Seasons’ Greetings and Happy & Prosperous New Year 2014"

You are all aware that our Industry is seriously affected with the recent notifications issued by the Department of AYUSH.

Our Association requested for an urgent meeting with Secretary, Department of AYUSH specially to discuss the issues emerging from the Notification on implementation of the new labeling guidelines and Prefix & Suffix.

Minutes of the meeting received from the Department of AYUSH is published in Page No. 6 & 7 of this issue.

Further meeting also was held with State licensing authorities, Drug Controller on 20th December 2013 in Department of AYUSH. Dr. J.L.N. Sastry represented ADMA in this meeting. The Notes on AYUSH meeting with the DCC and ADMA prepared by Dr. J.L.N. Sastry was already circulated to all the members for their information.

We are awaiting to receive the final minutes from the Department of AYUSH. Our Association also sought an appointment with the Chairman, National Biodiversity Authority to resolve the issues on Biodiversity Act and Rules, Access and Benefit sharing. Chairman was kind enough to give us an appointment for 3rd January 2014. Report of the Meeting would be circulated to all the members.

I am happy to note that following new members were enrolled as a Annual member of our Association from 1st October 2013 to 31st December 2013.

1. M/s. Hiya India Biotech Pvt. Ltd, Rajasthan
2. M/s. Panasia Herbal Pvt Ltd, Indore
3. M/s. Veda Ayurvedics Pvt Ltd, Kerala
4. M/s. Valiyeri Vaidyasala, Kerala
5. M/s. Punarnava Nutraceuticals & Herbs Pvt Ltd
6. M/s. Veda Herbs And Drugs Pvt. Ltd, Kerala
7. M/s. Rasathanthra Pharmaceuticals Pvt Ltd, Kerala
8. M/s. Chaitanya Ayurveda Pharmaceuticals, Kerala
9. M/s. Santosh Pharmacy, Kerala
10. M/s. SNA Oushadhasala (P). Ltd, Kerala
11. M/s. Sreedhareeyam Ayurvedic Medicines (P) Ltd., Kerala
12. M/s. Vasudeva Vilasam Herbal Remedies P Ltd, Kerala
13. M/s. Nagarjuna Herbal Concentrates Ltd, Kerala
14. M/s. Atul Medical, Pune

I warmly welcome all of them and look forward to their active participation in the association’s activities.

Dr. P.M. Varier
President - ADMA
From the Secretary’s Desk

Dear Members,

A gist of activities and updates are given below for your information.

1. Joint Adviser (Ayurveda) requested ADMA to send a suitable Note based on the authentic information gathered from classical texts and scientific papers to endorse the safety and efficacy of Mercury. ADMA sent the said Note prepared by Dr. Sastry to Department of AYUSH on 1-10-2013.

2. Vide letter dated 3-10-2013 Department of AYUSH had intimated to the Associations Abbreviations for various Plant ingredients which was circulated to all our members.

3. Our Association received letter dated 10-10-2013 from the Department of AYUSH advising Drug Manufacturers to ensure shelf life or expiry date rules for various dosage forms of ASU medicines are enforced or adopted in spirit without making any deviation in the legal provisions under Drugs & Cosmetics Rules 161 B notified vide GSR No. 764(E) dated 15-10-2009. The same was circulated to all our members for their information.

4. Our Association had once again requested vide our letter no. 1013/ADMA/373/AYUSH/Label dated 15-10-2013 to consider extension of implementation of GSR No. 844(E) dated 26-11-2012 with regard to new labeling provisions to 1st December 2014, to allow for a mitigation in hardship and also make it possible practically to implement the Notification. We had received response from Department of AYUSH vide their letter dated 29-10-2013 informing that extension of time for implementing the said notification has not been agreed to.

5. Department of AYUSH had requested comments on draft rules for Free Sale and Non-Conviction Certificates and our comments were sent vide our letter no. 1013/ADMA 379/AYUSH dated 18-10-2013.

6. Additional Principal Chief Conservator of Forests Protection and Member Secretary requested the comments on drafting of rules under Indian Forest Act 1927. We had sent our suggested input vide our letter no. 1013/ADMA/380/PCCF-Nagpur dated 18-10-2013.

7. Dr. Vipin Sharma, International Co-operation, Department of AYUSH, requested to provide comments/views on foreign trade policy 2014-19 keeping in mind the trade of AYUSH industry, Medicinal Plants/herbs and issue related to AYUSH system to be taken up with Ministry of Commerce. ADMA sent comments on Foreign Trade Policy (2014-19) vide letter ref. no. 1013/ADMA/389 dated 26-10-2013.

8. We had made our representation to Mrs. Santosh Chowdhary, Hon’ble Minister of State, Ministry of Health & Family Welfare, New Delhi on some of the very important matters concerning the AYUSH industry such as matters related to National Biodiversity, implementation of GSR No. 844(E) dated 26-11-2012, regulations that obstruct the smooth flow of trade in Medicinal plant due to provision of the Indian Forest Act 1927, Wild Protection Act 1972, Schemes that will progress AYUSH industry in the 12th five year Plan.

9. 4th China (Taizhou) International Medical Expo was held in China from 8th to 10th November 2013. Sandu Brothers Pvt. Ltd, Sandu Pharmaceuticals Ltd. and &Vasu Healthcare Pvt. Ltd. represented the Ayurvedic sector in this delegation. Brief write up is published in Page no. 7 of AYURBIZ.

10. Dr. Kavita Gupta, Addl DGFT(EFC), Mumbai requested us to forward the problems of Members relating to DGFT and Customs Authorities pertaining to exports to Russia, Israel and China for consideration in the meetings with the respective Consul Generals regarding exports to above countries. Members were requested to give their feedback vide letter ref. no. 1113/ADMA/413 dated 13-11-2013.

11. ADMA made a submission vide letter no. 1113/ADMA 421A/AYUSH/Prefix-Suffix dated 21-11-2013 to Department of AYUSH in regard to Implications with GSR 704(E) dated 25-10-2013 on Prefix-Suffix and Resemblance- Mimicking issues.

12. Our Association requested the Secretary, Department of AYUSH for an urgent appointment to discuss on GSR 704(E) dated 25-10-2013 regarding Prefix-Suffix as the said Notification would seriously affect all our ASU Industry irrespective of economic size. The Secretary was kind enough to give us an opportunity to meet his good self on 26-11-2013 to appraise him about the serious effect on ASU industry by implementation of the said notification.
The following members represented our Association in this meeting:

- Dr. P.M. Varier, President, ADMA
- Mr. Nimish Shroff, Joint Secretary, ADMA
- Mr. Ranjit Puranik, Vice-President (W), ADMA
- Dr. J.L.N. Sastry, Member, Managing Committee
- Dr. Vijendra Prakash, Member, ADMA.

Record Note of discussion taken at the meeting with Secretary, AYUSH has already been circulated to all the members.

13. NBA invited the Representatives of ADMA for participating in the 2nd Meeting of the reconstituted Expert Committee on Medicinal Plants which was held on 26th & 27th November, 2013 at Chennai. Dr. Amit Agarwal, Director, M/s. Natural Remedies Pvt. Ltd, Bangalore and Member, Managing Committee, ADMA represented ADMA in this meeting.

14. NBA also invited the Representatives of ADMA for participating in the National dialogue meeting regarding Traditional Knowledge (TK) and Access Benefit Sharing (ABS) which was held on 29-30 November, 2013 at Hyderabad. Mr. Rajendra Dobriyal, Senior Regulatory Affairs Manager, M/s. Hindustan Unilever, Gurgaon and Member, Managing Committee, ADMA represented ADMA in this meeting.

15. Member Secretary & Dy. DGFT (EFC) requested us to inform all issues relating to DGFT pertaining to export facilitation for consideration in the EFC meeting scheduled to be held in December 2013. Members were requested to give their feedback vide letter ref. no. 1213/ADMA/436 dated 10-12-2013.

16. National Medicinal Plant Board, vide their letter dated 7th November 2013, informed the Association that they have engaged M/s Centre for Research, Planning and Action (CERPA), New Delhi, as the agency for the purpose of submitting periodical reports on records of raw material used by Ayurveda, Siddha and Unani (ASU) manufacturing units in respect of years 2010-11, 2011-12 and 2012-13 as per Schedule T-1 proforma. In view of the same they have requested all our members to furnish the required details in Schedule T-1 proforma to M/s, CERPA for the said years. Our Association request all our members to furnish the required details in Schedule T proforma to the President, Centre for Research, Planning and Action (CERPA), 16, Dakshineshwar, 10, Hailey Road, New Delhi-110001. FAX 011-23329216. email: nmbp.cerpa@gmail.com, spahuja@nde.vsnl.in

17. The Secretary, Ministry of Health & Family Welfare, Department of Health & Family Welfare issued the draft Notification GSR 702(E) dated 24-10-2013 in regard to Phyto Pharmaceutical Drugs. Our Association made a submission on the basis of suggestion made by Member vide letter ref. no. 1213/ADMA/444 dated 19-12-2013 to Secretary, Dept of Health & Family Welfare, New Delhi and the copy of the same was endorsed to Secretary, Department of AYUSH.

18. MoEF invited the Representatives of ADMA for participating in the National Consultation Meeting held on 20th and 21st December 2013 at New Delhi. Dr. Amit Agarwal, Director, M/s. Natural Remedies Pvt. Ltd, Bangalore and Member, Managing Committee, ADMA, Mr. Rajendra Dobriyal, Senior Regulatory Affairs Manager, M/s. Hindustan Unilever, Gurgaon and Member, Managing Committee, ADMA and Dr. N.B. Brindavanam, Head, BRD Group, M/s. Dabur India Ltd, Ghaziabad and Member, ADMA represented ADMA in this meeting.

19. A DCC meeting was called by Department of AYUSH on 20th December 2013 and ADMA Representative was also invited for the deliberations in this meeting on the recent regulatory Notifications and other licensing issues. Dr. J.L.N. Sastry represented ADMA in this meeting. Notes on AYUSH meeting with DCC and ADMA has already been circulated to all members for their information.

Members are requested to send their feedback as and when requested to enable us to make effective submission.

Chandrakant Bhanushali
Hon. General Secretary

Members who have not yet renewed their membership subscription are requested to renew immediately.
Sal tree - Classification

<table>
<thead>
<tr>
<th>Classification</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kingdom</td>
<td>Plantae</td>
</tr>
<tr>
<td>Division</td>
<td>Magnoliophyta</td>
</tr>
<tr>
<td>Class</td>
<td>Magnoliopsida</td>
</tr>
<tr>
<td>Order</td>
<td>Malvales</td>
</tr>
<tr>
<td>Family</td>
<td>Dipterocarpaceae</td>
</tr>
<tr>
<td>Genus</td>
<td>Shorea</td>
</tr>
<tr>
<td>Species</td>
<td>S. robusta</td>
</tr>
<tr>
<td>Scientific Name</td>
<td>Shorea Robusta</td>
</tr>
<tr>
<td>Found In</td>
<td>Bandhavgarh National Park, Corbett National Park and Dudhwa National Park in India</td>
</tr>
</tbody>
</table>

Other names:
Shala, Sarai, Sargi, Salwa, Sakhu, Sakher, Shal, Kandar and Sakwa are the other names used for the Sal tree.

Description:
Sal is a large sub deciduous tree. It is up to 30 meter high. Sal tree is seldom completely leafless. It has large leathery leaves and yellowish flowers. They have tough texture. Young trees have a linear crown, which becomes rounder and flatter with aging. The sapwood is whitish in colour, thick and is less durable. The heartwood becomes dark brown to black in colour on exposure. The wood pores are filled with resin.

Location:
Sal tree are found in Assam, Nepal, Bengal and on the bank of the Yamuna river. In Haryana Sal can be found in the Morni Hills and the Kalesar forests. Sal tree grows in North East and Central India up to 1700 meter elevation. It is widely grown in the foothills of the Himalayas. Sal trees are also found in the Bandhavgarh National Park, Corbett National Park and Dudhwa national Park in India.

Cultivation methods:
Sal tree requires well drained, moist and sandy loam soil. It can grow in any type of temperature. It is mostly propagated through cuttings. In dry conditions it sheds its leaves from February to March. New leaves appear in the month of April and May. The flowers mature into fruit in summers and the seeds ripen in June -July.

Medicinal uses:
The resin is used in the indigenous system of medicine as an astringent and detergent and is given in diarrhea and dysentery. It is also used as an ingredient of ointments for skin diseases and in the ear troubles. It is also used in the foot care cream. The fruits of the Sal tree are used in the treatment of excessive salivation, epilepsy, and chlorosis. The powered seeds have insecticides properties. The powered seeds are even used to treat dental problems. It cleanses the skin of oily secretion and is used as the cleanser for washing hair.

Other uses:
The leaves of the Sal tree are used by the tribal people for preparing rice cakes and for smoking. The leaves are used to make platters, bowls, small baskets and many more. Distilled leaves produce an oil which is used in perfumery. It is also used in flavouring chewing gums and tobacco. Its dried and fallen leaves are used as fertilizers. It is used for caulking ships and boats. The oil that comes out from its seed is edible and is known as Sal butter. It is often used in cooking and for the burning in the oil lamps. The seeds of the Sal tree are used for fat extraction. Its oil is even used for adulterating ghee. Tribal people give marriage invitation in the form of folded Sal leaves, with the little bit of turmeric and rice inside it.

Cultural Importance:
Sal tree is worshiped among the Buddhist and Hindus in India. It is mentioned in many scriptures that the Buddha was born and died under the Sal tree. A branch of the tree bend down to support his mother Maya and as soon as he held on the tree, the baby appeared. Sal tree has special significance in the festivals and marriages of Adivasis. A pole of the Sal tree is considered very important and unless the bridegroom sits on the altar made of tree of Sal, the marriage has no meaning. It also holds great value in the lives of the indigenous populace of Chotanagpur plateau. It is the main attraction of the festival of Sarhul, which means Sal Blossoms Festival. The whole festival revolves round the Sal tree.  

subject: Maintenance of records of raw material used by Ayurveda, Siddha and Unani (ASU) Licensed drug Manufacturers.

Sir,

The National Medicinal Plants Board (NMPB). Department of AYUSH has been set-up to coordinate matters related to development of medicinal plants sector and to formulate / implement schemes in this regard. To this end a reliable database of raw material consumed by ASU licensed drug manufacturers is required for formulation of a better implementable policy for development of the sector.

2. As you are aware, Government has amended the Drugs & Cosmetics Rules 1945 requiring the licensed manufacturing units of Ayurveda, Siddha & Unani drugs to maintain and furnish record of the raw material used in the manufacture of their products to the State Drug licensing authorities and to the National Medicinal Plants Board on an annual basis vide notification No. K.110201212006-DCC(AYUSH), dated OP July, 2008.

3. A reference is invited to Rule 157A of the Drugs and Cosmetics Rules, 1945 - reproduced below:-

“157A.Maintaining of records of raw material used by each licensed manufacturing unit of Ayurveda, Siddha and Unani drugs in the preceding financial year. Each licensed manufacturing unit of Ayurveda or Siddha or Unani drugs shall be required to keep record of raw material used by each licensed manufacturing unit of Ayurveda, Siddha and Unani drugs in the preceding financial year and to submit record in the proforma given in schedule T-1 in respect of all raw materials utilized by that unit in the manufacture of Ayurveda or Siddha or Unani drugs in the preceding financial year, by the 30th day of June of the succeeding financial year with the State Drug Licensing Authority of Ayurveda or Siddha or Unani drugs and National Medicinal Plants Board or any agency nominated by the National Medicinal Plant Board for this purpose.”

4. In this connection, it is hereby informed that NMPB has engaged M/s Centre for Research, Planning and Action (CERPA), New Delhi as the agency for the purpose who will submit periodical reports on records of raw material used by ASU manufacturing units in respect of years 2010-11, 2011-12 and 2012-13 as per Schedule T-1.

5. In view of the above, you are requested to kindly furnish the required details in Schedule T Proforma to M/s CERRA, New Delhi in respect of the years 2010-11, 2011-12 and 2012-13. Address of M/s CERPA for communication:

The President, Centre for Research, Planning and Action (CERPA),
16, Dakshineshwar, 10, Halley Road, New Delhi-110001.
E-mail: nmpb.cerpaftmail.com
spahuiaande.vsnl.net.in Fax: 011-23329216

8. For any clarification or further information contact may be made either to:

(i) Manager (Marketing & Trade) — Tel: 24651300 or Assistant Advisor (Botany) — Tel: 24851821 of National Medicinal Plants Board, Department of AYUSH, Room No. 309, 3. Floor, AYUSH Bhawan, B-Block. GPO Complex. INA Market, New Delhi — 110023.

(ii) The President or Sh. Rajendra Singh, Director, Centre for Research, Planning and Action (CERPA), 16, Dakshineshwer, 10, Hailey Road. New Delhi-110001; Phones: 011-23326955. 23355170, Fax 23329216, Email: rim b.c_12_22Ata:2_1m. spahuiaende.vsnl.net.in

You are requested to furnish the above specified Information as per prescribed proforma for the above said period.


(Meenakshi Negi)
Dy. CEO
Government of India Ministry of Health & Family Welfare Department of (AYUSH)
(NATIONAL MEDICINAL PLANTS BOARD)
On the request of General Secretary, Ayurvedic Drug Manufacturers Association (ADMA), Mumbai, an urgent meeting was called by Secretary (AYUSH), Shri N. Sanyal with industry representatives on 26th November 2013 to discuss the issues emerging from the notification banning the use of prefix & suffix on the labels of ASU medicines. Following attended the meeting-

i) ADMA representatives • Dr. P.M. Varier, President, ADMA • Mr. Ranjit Puranik, Vice-President, ADMA • Dr. Nimish Shroff, Jt. Secretary, ADMA • Dr. J. L. N. Sastry, Executive Member, ADMA • Dr. Vijendra Prakash, Member, ADMA

ii) Departmental Officers • Shri Bala Prasad, Joint Secretary (AYUSH). • Dr. D. C. Katoch, Joint Advisor (Ay.). • Dr. G.C. Gaur, Technical Officer (DCC).

2. At the outset industry representatives thanked the Secretary (AYUSH) for holding the meeting at a very short notice to discuss the concerns of ASU Drug Manufacturers over the recently notified Drugs & Cosmetic Rules. In response to the industry’s reiteration for extension of time to adopt the new labeling provisions, Secretary (AYUSH) clarified that one year’s time for implementation was given in the notification after due consultation with the industry and there is no scope at this stage to consider the demand as the notification was laid in the Parliament within Apulated timeframe and the enforcement in the states will take its own course. However, as, request by the industry to the Department to issue clarification to the Licensing Authorities for not treating change of labels as a case of fresh licensing has been agreed to and letter in this regard is being issued.

3. Shri Ranjit Puranik and Mr. Nimish Shroff referred to the earlier demand of ADMA for the prospective date for implementation of the amended notification of GSR No. 704(E) dated 25/10/2013 and mentioned that the industry, who has developed their brand products over 10-15 years, will be badly affected with the new provisions of banning the use of prefix/suffix with the names of ASU formulations. In the notification no time is provided under clause IC for the industry to adapt and it may lead to the situation that entire section 3(h) category products cease to exist if somebody starts interpreting resemblance-mimicking of names from the date of notification itself. Notification was challenged for not carrying the clarity of intent to provide one year time for the industry to change. Quoting some examples Dr P.M. Varrier and Dr JLN Sastry questioned the adverse impact of the notification on the traditional use of prefixes in existing formulations both under 3(a) and 3(h) categories and reiterated to make the enforcement from prospective effect leaving the products already licensed.

4. Secretary (AYUSH) informed that this is not in our hand at this stage to hold the notification due to commitment made to the Parliament for notifying the said Rules in compliance of the verdict of Hon’ble High Court of Himachal Pradesh and recommendation of ASUDTAB. The Rules as notified have to be laid in the forthcoming session of the Parliament and Secretary (AYUSH) also stated that any apprehensions on the provisions and impact of the recent notification can be debated and necessary clarifications, if needed, may be issued to the State Drug Licensing Authorities with due discussions and consultations.

5. Industry representatives specifically raised the following concerns against the possible implications of enforcing the notification in present form-

a) In clause IB of the notification though time of one year is given to the manufacturer to renew the license for generic formulations in accordance with the new provisions, but the proviso to the Rule seems not to allow manufacturing during this period with existing license. Notification is also not clear whether the lead period of one year for adoption is applicable for clause IC pertaining to prevention of mimicking or resembling names in Patent/Proprietary formulations.

b) Traditional use of differentiating prefixes used by the industry like Cheriya, Periya, Valiya etc for anonymous formulations in Kerala will hamper, if the nomenclature on the basis of first ingredient of such formulations is introduced for classical ASU medicines falling in the category defined in section 3(a) of Drugs & Cosmetics Act.

c) There could be practical confusion in dealing with multiple formulations with same name like Chandraprabha Vati, Triphaladi Churna, Ashwagandhadi Churna etc. Composition of such formulations varies in different authoritative texts and there are instances of difference in the ingredients and proportion of ingredients in the AFT and the classical text.

d) Companies having developed brand names of their products and legally allowed for so many years to manufacture and sell them may not be forced to change at a short notice. 5-10 years’ time should be given to the industry, as done for
enforcing GMP, to adapt to the new regulatory requirements for preventing the use of prefix and suffix in generic formulations. e) Use of company’s name before the name of the product may not be considered as prefix/suffix as the brand names have been developed with lot of investment over the years to imbibe consumers’ confidence.

f) Clarity is required under clause IC of the Rule in defining mimicking or resembling, otherwise Licensing Authorities may interpret the names of 3(h) products differently and decide in their own way in different states. In this regard, use of names of single herbs/minerals like Sallaki, Shilajeet, Guduchi etc as given in authoritative texts and nouns like Charak, Bhaskar, Chyawan etc may not be taken as mimicking.

g) Certain Patent or Proprietary Ayurvedic formulations marketed for many years may be forced to cease as their names or name parts mimic with the classical formulations like Amritanjan Balm simulates a classical formulation listed in Bharat Bhaishajya Ratnakar.

h) Explaining the example of Paracetamol, which is promoted as generic as well as branded medicine by many companies, restriction in the nomenclature of ASU medicines may not be imposed for the growth of ASU drug industry.

6. Industry representatives suggested that in order to facilitate commercial growth of ASU products, the entire issue of nomenclature needs to be revisited. It was emphasized that the industry has no issue over not allowing the use of prefixes and suffixes with the products licensed under Section 3 (a), but allowing the same for 3 (h) category of products would help brand building and prevent the problem of interpreting mimicking. Industry representatives while agreeing for the need of protecting the names of classical formulations demanded to reconsider the clause I(C) of the notification in favour of patent and proprietary formulations, on which lot of investment and R&D is done to build up the brand names.

7. Departmental Officers stated that the Central Government is advised by the ASUDTAB and ASUDCC in technical and regulatory matters of ASU drugs and if warranted the issue raised by the industry can be referred to ASUDTAB after discussion with the State Licensing Authorities. After detailed discussions over the pros and cons of the notification, it was decided to adopt the following course of action-

a) Industry associations shall give in writing their concerns with justification with unanimity.

b) Department will call a meeting of State Licensing Authorities in third week of December 2013 to discuss inter alia the enforcement issue of the notification. ASU drug industry will be given opportunity to present its concerns in that meeting.

c) Issues raised by industry in writing will be duly examined in the Department for necessary actions and legal advice may be solicited about the prospective applicability of lead time of one year under clauses 1B and 1C in GSR No. 704(E) dated 25-10-2013 and the necessity of issuing an amendment in the provisions following the laid down procedure.

Meeting ended with a vote of thanks to the Chair.

Indian firms participated for the first time in the China (Taizhou) International Medical Expo held in Taizhou, Jiangsu from November 8-10, 2013. A total of 18 Indian pharmaceutical manufacturers participated in the exhibition with the support of PHARMAEXCIL in the Expo. Participants from: 1. M/s Sandu Brothers Pvt. Ltd. 2. M/s Sandu Pharmaceuticals Ltd. 3. M/s Vasu Healthcare Pvt. Ltd. representing Ayurvedic sector participated in this delegation. The Indian pavilion was inaugurated by Mr. Zheng Lei, Party Secretary of Taizhou, Mr. Sudhanshu Pandey, Joint Secretary, Ministry of Commerce and Consul General. A briefing session Chinese pharma market and regulatory framework and a business-to-business meeting between Indian and Chinese pharma companies was also organized on this occasion by Taizhou Medical City and China Food and Drug Administration. For study purpose, the exhibition has provided good platform.
# Forthcoming Events

**Conference on Nutraceuticals, Functional Foods and Dietary Supplements**  
Organised by FICCI-HADSA, 17th January 2014 at Sci-Tech Centre

**25th Autumn Fair, Manama**  
Organised by ITPO, 21st to 29th January 2014 at Bahrain International Exhibition Centre, Bahrain. [http://www.theautumnfair.com](http://www.theautumnfair.com)

**The Partnership Summit 2014**  
Organised by CII, 27th to 29th January 2014 at Taj West End, Bangalore  
[www.partnershipsummit.com](http://www.partnershipsummit.com)

**National Arogya Fair**  
Organised by Indian Chamber of Commerce, 7th and 10th February 2014 Kolkata Maidan, Kolkata, [http://www.indianchamber.org/event](http://www.indianchamber.org/event)

**Two days’ National Seminar on “Purishavaha Srotas-Concept to Clinical”**  
Organised by Vaidya Vilas Nanal Research Foundation, 9th and 10th February 2014 at Lokmanya Auditorium, Kesari Wada, Pune.

**AAyurveda World Summit & Expo 2014**  
Organised by Octagon Communications Pvt Ltd, 14th to 16th February 2014 at Gandhinagar, Gujarat. [www.octogoncom.in](http://www.octogoncom.in)

**Global Ayurveda Festival & Arogya Expo (GAF)**  
Organised by the Centre for Innovation in Science & Social Action (CISSA), jointly with the Government of Kerala and the Ayurveda Fraternity of Kerala, 20th to 24th February 2014 at Kochi, Kerala. [www.gaf.co.in](http://www.gaf.co.in)

**AROGYA (Health & Beauty) Fair**  
Organised by ITPO, 20th - 23rd March, 2014 at NSE, Complex, (BCEC) Goregaon, Mumbai

**The India Show Kazakhistan**  
Organised by Confederation of Indian Industry, 27th -30th March 2014 at Atakent Exhibition Centre, Almaty-Kazakhstannot.[www.cii.in](http://www.cii.in)